Chapel Hill, NCNCT05570721Now EnrollingIRB Ready

Menopause Clinical Trial in Chapel Hill, NC

Access cutting-edge menopause treatment through this clinical trial at a research site in Chapel Hill. Study-provided care at no cost to qualified participants.

Sponsored by University of North Carolina, Chapel Hill

Quick Self-Assessment

See if you qualify for this Chapel Hill location

Preparing your pre-screening questions…

Expert Care in Chapel Hill

Access menopause specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related menopause treatment provided free

Apply for This Chapel Hill Location

Check if you qualify for this menopause clinical trial in Chapel Hill, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chapel Hill

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chapel Hill site if eligible
  4. 4Begin participation

About This Menopause Study in Chapel Hill

Depression is a known risk factor for cardiovascular disease (CVD), and this comorbidity contributes significantly to the morbidity and mortality of women. The menopausal transition or perimenopause is a period of vulnerability for both depression and CVD, making it a key time to study this critical public health issue. This research will preliminarily explore whether disruption in two novel stress pathways 1) the renin-angiotensin-aldosterone system (RAAS) and autonomic nervous system (ANS) and their relationship may underlie the link between these illnesses. Findings will provide important insight into potential mechanisms by which depression during perimenopause may increase risk for CVD in midlife women, which will inform potential risk reduction and treatment strategies that can improve health outcomes in this population.

Sponsor: University of North Carolina, Chapel Hill

Who Can Participate

Inclusion Criteria

Women ages 44-55 in the late perimenopause reproductive phase. Perimenopausal status will be determined based on menstrual cycle history. We will enroll women who have had an interval of amenorrhea of at least 60 days but \<1 year consistent with the late menopause transition
Participants in either group may be on antidepressant medications (for any indication), but doses must be stable within 30 days of study participation

Exclusion Criteria

History of bipolar diagnosis or primary psychotic disorder for both groups; prior history of depression in the no-perimenopausal depression group
In the perimenopausal depression group, current depressive symptoms that are "severe" based on score of Center for Epidemiologic Studies Depression Scale (CES-D) \>25.
Current alcohol or substance use disorder
Current suicidal ideation with intent and history of suicide attempt within 2 years of study participation
Current or recent use of the following medications:
Hormonal agents (e.g., hormone replacement therapy or combined oral contraceptive pills)within the past 30 days
Oral, inhaled, or injected steroids within the past 90 days
Blood pressure medications (e.g., Angiotensin-Converting Enzyme (ACE) inhibitors) within the past 90 days
Antihistamines within the past two weeks
Other medications determined by the study team to impact the RAAS (e.g., spironolactone).
Current cigarette or nicotine use
Current diagnosis of cardiovascular disease, type I or II diabetes, or other medical condition which the study team determines could impact study outcomes

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chapel Hill?

Yes, this clinical trial (NCT05570721) has an active research site in Chapel Hill, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Menopause Treatment Options in Chapel Hill, NC

If you're searching for menopause treatment options in Chapel Hill, NC, this clinical trial (NCT05570721) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chapel Hill research site is actively enrolling participants for this clinical trial. You'll receive care from experienced menopause specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all menopause clinical trials near you to find additional studies recruiting in your area.

More Menopause Trials in Chapel Hill, NC

See all menopause clinical trials recruiting in Chapel Hill — not just this study.

Browse Menopause Trials in Chapel Hill →

Browse More Trials by Condition

Menopause TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Chapel Hill?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chapel Hill, NC